Federal Agencies Fund Ibogaine Research for PTSD
The Trump administration announced on November 12 that federal agencies would invest in research on ibogaine, a powerful psychedelic being considered as a possible treatment for post-traumatic stress disorder, addiction and other mental health conditions. Health and Human Services chief Robert F. Kennedy Jr. said his department would provide up to $4.9 million for work to prepare for U.S. studies. A separate announcement described a federal investment of more than $25 million involving HHS and the Department of Veterans Affairs to speed research. The initial funding is for groundwork, not patient trials, Kennedy said.
The preparatory work is expected to address how the drug can be manufactured and dosed, and how studies can be designed. VA Secretary Doug Collins said the effort would put safety and high-quality research first, while also recognizing the urgency of finding treatments for veterans with PTSD.
Ibogaine comes from a West African shrub and can cause intense hallucinations, nausea, vomiting and tremors. It can also trigger potentially fatal irregular heart rhythms. The drug is illegal in the United States and is classified alongside LSD and ecstasy. Its restricted status has kept U.S. research largely stalled for decades.
Advocates, including veterans’ groups, say ibogaine could help people with difficult-to-treat PTSD, depression and opioid addiction. Kennedy said the government would obtain information and clinical advice from Beond Inc., a Texas company that has treated more than 3,000 people with ibogaine in Mexico. Further funding could examine its use for addiction. The administration’s move follows an April executive order directing agencies to speed research and review of psychedelics for mental health conditions.
Federal Research Could Open a Path to Ibogaine Treatment
Federal agencies are moving toward U.S. research on ibogaine, a psychedelic that veterans’ groups and other advocates say may help people with severe PTSD, depression and opioid addiction. The administration announced funding on November 12, including up to $4.9 million from Health and Human Services for groundwork and a separate investment described as exceeding $25 million across HHS and Veterans Affairs.
The first dollars are not for patient trials. They are intended to prepare for studies by addressing manufacturing, dosing and research design. VA Secretary Doug Collins said the effort would focus on safety and strong research, while stressing the urgency of finding options for veterans with PTSD. HHS Secretary Robert F. Kennedy Jr. said the government would obtain information and clinical advice from Beond Inc., which has treated more than 3,000 patients in Mexico.
Ibogaine’s potential has been difficult to study in the United States because it is illegal and tightly restricted. That restriction has left much of the available information coming from people treated abroad. The drug carries serious risks, including potentially fatal heart rhythm problems, making careful clinical research essential—not a reason to leave patients and veterans without evidence-based answers.
The administration’s April order called for faster research and review of psychedelics for mental health conditions. Further federal funding may examine ibogaine for addiction, while the initial work is meant to establish a safer basis for U.S. studies.
Ibogaine Research Must Put Safety Ahead of a Fast Approval Push
The Trump administration is putting federal money behind ibogaine research, with a focus on preparing studies for PTSD, addiction and other mental health conditions. HHS Secretary Robert F. Kennedy Jr. said his department would provide up to $4.9 million for preparatory work; another announcement described an investment of more than $25 million involving HHS and Veterans Affairs.
That funding is for groundwork, not trials treating patients. Researchers must address manufacturing, dosing and study design before U.S. patient research can proceed. VA Secretary Doug Collins said safety and high-quality research would come first. That standard matters: ibogaine can cause hallucinations, nausea, vomiting and tremors, and can also lead to potentially fatal irregular heart rhythms.
The drug remains illegal in the United States, and its restricted status has limited domestic study for decades. Advocates point to people treated in Mexico and to possible benefits for veterans with PTSD and people facing addiction. Beond Inc., a Texas company that has treated more than 3,000 patients in Mexico, is expected to supply the government with findings and clinical recommendations. But overseas treatment experience is not a substitute for carefully designed U.S. studies.
The administration’s April order urged agencies to accelerate psychedelic research and review. Any push to move faster should be matched by the safety-first approach Collins described, especially as further funding may explore ibogaine for addiction.
Reported by The Philadelphia Inquirer, The Washington Examiner, PBS NewsHour, PhillyVoice, FOX 10 Phoenix.
